Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MRSA: Binary typing as screening method for WGS

ABSTRACT: Hospital MRSA outbreaks: Binary typing as a screening method for WGS, and the role of the environment in transmission

PROVIDER: PRJEB28052 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Development of a glycan microarray based method for ABO blood typing

Project description:Purpose: This study uses a high-throughput glycan microarray to develop a novel method to assign ABO blood type. The method will then be applied to samples from patients treated with PROSTVAC to determine if blood type correlates with survival Results: Many blood group A and B antigens correlate with blood type. Blood typing is best achieved using a combination of 10 signals Conclusion: ABO blood type can be determined with greater than 97% accuracy using only 4 microliters of serum.

2016-04-28 | GSE68403 | GEO

Evaluation of WGS-based spa typing

Project description:Evaluation of WGS-based spa typing of S. aureus

| PRJEB7089 | ENA

WGS for typing of Legionella pneumophila

Project description:Evaluation of whole genome sequencing for the epidemiological typing of Legionella pneumophila

| PRJEB17630 | ENA

Class I Typing

Project description:Class I Typing

| PRJEB33618 | ENA

Clostridium difficile typing

Project description:Clostridium difficile typing

| PRJEB656 | ENA

Listeria monocytogenes Typing

Project description:Typing of Listeria monocytogenes.

| PRJEB5481 | ENA

GAS emm-typing tool for WGS data

Project description:Whole genome sequencing of Group A Streptococcus: development and evaluation of an automated pipeline for emm gene typing.

| PRJEB17673 | ENA

WGS- versus ORF5-Based Typing of PRRSV: A Belgian Case Study.

Project description: Not available

| S-EPMC8707199 | biostudies-literature

EPIDEMIOLOGICAL TYPING OF SERRATIA MARCESCENS

Project description:EPIDEMIOLOGICAL TYPING OF SERRATIA MARCESCENS

| PRJEB28358 | ENA

YAP and TAZ Dictate Binary Pan-Cancer Superclasses

Project description:This SuperSeries is composed of the SubSeries listed below. We defined pan-cancer binary classes based on distinct expression of YAP (and its paralog TAZ/ WWTR1) and YAP-responsive adhesion regulators. Combining informatics with in vivo and in vitro gain- and loss-of-function studies across multiple murine and human tumor types, we showed that opposite pro- or anti-cancer YAP activity functionally defines binary YAPon or YAPoff cancer classes that express or silence YAP, respectively. Essentially all leukemia and lymphoma fall into the YAPoff class, as do multiple neural and neuroendocrine YAPoff solid cancers. YAPoff solid cancers are frequently RB1-/-, such as retinoblastoma, small cell lung cancer and neuroendocrine prostate cancer. YAP-silencing was intrinsic to the cell-of-origin, or acquired with lineage-switching and drug-resistance. The binary cancer groups exhibit distinct YAP-dependent adhesive behavior, and pharmaceutical vulnerabilities, underscoring clinical relevance. Mechanistically, whereas YAP induces cell cycle genes in YAPon cancers, extensive RNAseq data showed that forced YAP expression in YAPoff cancers instead activated adhesion genes that are normally co-silenced with YAP. YAP regulates both of these anti-cancer adhesive or pro-cancer cell cycle programs through the TEAD DNA binding family (TEAD1-4). YAP/TEAD targets AP1-bound enhancers in YAPon cancers, but Chipseq studies revealed that in YAPoff cancers, YAP/TEAD instead targeted elements co-bound with neural and neuroendocrine lineage-defining basic helix-loop-helix (bHLH) and Homeobox transcription factors (e.g. NEUROD, ASCL1, NKX2, OTX2). A CRISPR screen revealed that, among the adhesion regulators, ITGAV/ITGB5 pair are required for YAP induced cytostasis in YAPoff cancers. YAP is thus pivotal across all cancer, but in opposite pro- or anti-cancer ways, which define contrasting genetic and drug sensitivities.

2021-06-21 | GSE144975 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data